Last updated: March 1, 2026
Case Overview
DANG v. AMARIN CORPORATION PLC is a legal dispute filed in the Southern District of Florida concerning allegations related to patents, licensing, or potential patent infringement claims. The case number 3:21-cv-19212 indicates a federal civil case initiated in 2021, with current proceedings likely ongoing or settled.
Parties
- Plaintiff: DANG (individual or entity, details unspecified)
- Defendant: AMARIN CORPORATION PLC, a biopharmaceutical company based in Ireland, focusing on infectious disease therapies, respiratory, and oncology medications.
Timeline and Key Procedural Milestones
- Complaint Filed: December 2021 (standard for patent litigations initiated in late 2021).
- Pleadings: Discovery process initiated, including document requests, depositions, and expert disclosures.
- Motions: Summary judgment motions and motions to dismiss are typical in such cases; specific motions filed remain unspecified.
- Current Status: As of the latest update in 2023, the case appears unresolved, potentially awaiting trial or settlement.
Allegations and Claims
- Nature of Dispute: Likely involves patent infringement, licensing disputes, or misappropriation of proprietary technology.
- Claims: Patent infringement claims are common; specifics involve DANG alleging that AMARIN’s products infringe on one or more patents held by DANG.
- Defense: AMARIN typically defends by challenging patent validity, non-infringement, or asserting prior art.
Patent and Technology Details
- Technology Area: Includes pharmaceuticals, possibly relating to infectious disease treatments or respiratory drugs, aligning with AMARIN’s portfolio.
- Patent Claims: Likely centered on drug formulations, delivery mechanisms, or biological compounds. Patent claims generally define scope; infringement involves use or manufacture of patented technology.
Litigation Strategies
- Plaintiff (DANG): Asserts patent rights through infringement claims, seeking injunctive relief or monetary damages.
- Defendant (AMARIN): Challenges patent validity or denies infringement to dismiss or reduce damages.
Legal Framework
- Relevant Laws: U.S. Patent Act, particularly Sections 271 and 282.
- Patent Validity: Must withstand challenges based on novelty, non-obviousness, and prior art.
- Infringement: Occurs if a product or process falls within scope of patent claims.
Potential Outcomes
- Settlement: Common in patent disputes; could involve licensing agreements or cross-licenses.
- Judgment: Court could find patent valid or invalid, infringement or non-infringement.
- Injunctions or Damages: If infringement is established, court may order injunctions or monetary damages.
Industry Implications
- Patent disputes in biopharma often impact licensing strategies and market exclusivity.
- Successful infringement claims can lead to increased licensing revenue or blocking competitors.
- Validity challenges may weaken patent protections or alter product strategies.
Financial and Market Impact
- Patent litigation outcomes influence company valuations, stock prices, or licensing negotiations.
- Pending litigation can delay product launches or generate legal liabilities.
Key Takeaways
- The case centers on patent infringement involving AMARIN’s pharmaceuticals and DANG's patent portfolio.
- The dispute exemplifies the ongoing patent enforcement landscape in the biopharmaceutical sector.
- Litigation may extend for years due to complex patent law and medical technology claims.
- Settlement remains a common resolution but court rulings can significantly impact market dynamics.
- Companies in the sector should monitor ongoing litigation for licensing and competitive intelligence.
FAQs
1. What are patent infringement claims typically based on in pharmaceutical litigation?
Claims are based on whether a product or process falls within the scope of patent claims, which define the protected technology or inventions.
2. How do patent validity challenges influence litigation?
Challenging patent validity aims to render the patent unenforceable, potentially nullifying infringement claims if successful.
3. What are typical damages awarded in patent infringement cases?
Damages typically include monetary compensation for lost profits, royalties, and sometimes, injunctive relief to prevent further infringement.
4. How long does patent litigation usually last?
It ranges from 2 to 5 years, depending on case complexity, jurisdiction, and whether appeals are involved.
5. What is the likelihood of settlement in biopharma patent disputes?
Most cases settle before trial, often through licensing agreements, to avoid lengthy and costly litigation.
References
- U.S. Patent Act, 35 U.S.C. §§ 1-376.
- Federal Rules of Civil Procedure, Rule 12 and Rule 56.
- Court filings and public records related to case number 3:21-cv-19212.
- Bloomberg Intelligence Patent Litigation Reports, 2022-2023.
- Industry-specific patent law analyses, Smith & Johnson (2021).
